Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
Evidence review

GLP-1 drugs and quality of life: what trial participants reported

Weight is measured on a scale. Whether someone can climb stairs, walk without knee pain or stop thinking about their weight is measured by asking them. This page covers what participants said.

Evidence-sourced
Written and fact-checked to our published editorial standards.Last updated 2026-11-12. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Moderate

In placebo-controlled trials, people taking semaglutide or tirzepatide reported better physical function and weight-related quality of life than people on placebo. In two trials, STEP-HFpEF and STEP 9, a questionnaire score was a primary endpoint alongside weight, so how participants felt was what the trial was designed to test. Placebo groups improved too, and every trial here was funded by the drug’s manufacturer.

Key takeaways

  • STEP-HFpEF (529 people with heart failure): KCCQ domain scores improved 6.7 to 9.6 points more with semaglutide than placebo.
  • STEP 9 (407 people with knee osteoarthritis): WOMAC knee pain fell 41.7 points with semaglutide and 27.5 points with placebo.
  • STEP 1, 2 and 4: more people on semaglutide reached a meaningful change in physical function, but 6.6% to 29.5% of the placebo groups did too.
  • SURMOUNT-1: physical scores rose with weight lost; the mental-health summary score rose 0.80 points even in the group that lost 20% or more.

Important limitation: Figures here come from each paper’s PubMed abstract, every trial was funded by the drug’s maker, and no trial compared the two drugs on these questionnaires.

Next action: If pain, breathlessness or mobility is the reason you are considering treatment, ask your prescriber whether a trial measured that outcome in people with your condition, not just weight.

Primary sources: STEP-HFpEF (PMID 37952180), STEP 9 (PMID 39476339), STEP 1–4 (PMID 38698650), SURMOUNT-1 (PMID 39497468)

General education only. Trial averages do not predict how any one person will feel on treatment.

Where a questionnaire was the point of the trial

Most obesity trials measure quality of life as a secondary question, after weight. Two of the trials below were built the other way round. STEP-HFpEF enrolled 529 people with heart failure and made the Kansas City Cardiomyopathy Questionnaire one of its two primary endpoints. STEP 9 enrolled 407 people with knee osteoarthritis and made knee pain, reported on the WOMAC scale, one of its two primary endpoints. In both, a score the participant gave was what the trial was powered to detect.

Each trial’s patient-reported results as stated in its PubMed abstract, read on 12 November 2026. Funding is shown beside the result because it applies to every row.
TrialWho took partQuestionnaireRole in the trialWhat participants reportedFunding
STEP-HFpEF
Semaglutide 2.4 mg, 52 weeks
Heart failure with preserved ejection fraction and obesityKansas City Cardiomyopathy Questionnaire (KCCQ)Primary endpointThe KCCQ Clinical Summary Score was one of two primary endpoints, alongside body weight. Treatment differences in all key KCCQ domains were 6.7 to 9.6 points. Split by baseline score, the difference was 10.7, 8.1 and 4.6 points; the confidence interval for the least-limited third (−0.6 to 9.9) crosses zero.Funded by Novo Nordisk A/S, per the paper's Sources of Funding statement.
STEP 9
Semaglutide 2.4 mg, 68 weeks
Obesity with moderate knee osteoarthritis and at least moderate painWOMAC pain score (0–100); SF-36v2 physical functionPrimary endpointKnee pain on the WOMAC scale was a primary endpoint, alongside weight. Pain fell 41.7 points with semaglutide; SF-36 physical function rose 12.0 points. Pain also fell 27.5 points with placebo, and physical function rose 6.5 points. Both groups received diet and activity counseling. Most of the improvement in pain happened in both groups. The difference attributable to the drug is the gap between them, not the 41.7-point figure.Funded by Novo Nordisk.
STEP 1–4
Semaglutide 2.4 mg, 68 weeks
Overweight or obesity, with and without type 2 diabetesIWQOL-Lite-CT (STEP 1 and 2); SF-36v2 (STEP 1–4)Confirmatory secondary endpointPhysical functioning was a confirmatory secondary endpoint. More participants on semaglutide than on placebo reached the threshold for a meaningful personal change in every trial reported. Between 6.6% and 29.5% of placebo participants also reached the meaningful-change threshold, depending on trial and questionnaire. The abstract reports confirmed superiority on SF-36v2 physical functioning in STEP 1, 2 and 4; it does not list STEP 3. In STEP 2, SF-36v2 Role Emotional was not numerically improved.PubMed lists Novo Nordisk A/S as funder; Novo Nordisk staff are among the authors, as is the lead author of the IWQOL-Lite-CT validation paper.
SURMOUNT-1
Tirzepatide, 72 weeks
Overweight or obesity without diabetesIWQOL-Lite-CT; SF-36v2; EQ-5D-5LSecondary analysisAll tirzepatide groups improved versus placebo. Among those who lost 20% or more of their weight, the IWQOL-Lite-CT Total score rose 24.7 points and the SF-36v2 Physical Component Summary 4.60. The SF-36v2 Mental Component Summary rose 0.80 in that same group. Grouping people by how much weight they lost is not a randomized comparison.Funded by Eli Lilly and Company, per the paper's funding statement.

Every result in the table favors the drug. The caveat beside each one is the part a headline usually drops, and in STEP 9 it is large: most of the fall in knee pain happened in both groups, so the effect attributable to semaglutide is the 14.2-point gap between 41.7 and 27.5, not the larger figure.

How many people reached a change they would notice

An average change can hide how many individuals actually felt different. The STEP 1–4 paper reports the share of each group that crossed a meaningful within-person change threshold: the size of change on a questionnaire that an individual would notice. Those shares are drawn below, drug and placebo side by side.

Share of participants reaching a meaningful change in physical function, semaglutide versus placebo, STEP 1, 2 and 4Percentage of each group reaching the meaningful within-person change threshold at week 68. STEP 1, IWQOL-Lite-CT Physical Function: semaglutide 51.8%, placebo 28.3%; STEP 2, IWQOL-Lite-CT Physical Function: semaglutide 39.6%, placebo 29.5%; STEP 1, SF-36v2 Physical Functioning: semaglutide 39.8%, placebo 24.1%; STEP 2, SF-36v2 Physical Functioning: semaglutide 41.0%, placebo 27.3%; STEP 4, SF-36v2 Physical Functioning: semaglutide 18.0%, placebo 6.6%. In every row the semaglutide share is higher, and in every row a substantial share of the placebo group also crossed the threshold.Semaglutide 2.4 mgPlaceboSTEP 1IWQOL-Lite-CT51.8%28.3%STEP 2IWQOL-Lite-CT39.6%29.5%STEP 1SF-36v239.8%24.1%STEP 2SF-36v241.0%27.3%STEP 4SF-36v218.0%6.6%
Share of each group reaching a meaningful change in physical function at week 68. The lighter bar is placebo.Source: Diabetes, Obesity and Metabolism 2024;26(7):2945–2955 (Rubino et al.), PMID 38698650.

STEP 1 on the IWQOL-Lite-CT Physical Function scale: 51.8% with semaglutide against 28.3% with placebo; STEP 2 on the IWQOL-Lite-CT Physical Function scale: 39.6% with semaglutide against 29.5% with placebo; STEP 1 on the SF-36v2 Physical Functioning scale: 39.8% with semaglutide against 24.1% with placebo; STEP 2 on the SF-36v2 Physical Functioning scale: 41.0% with semaglutide against 27.3% with placebo; STEP 4 on the SF-36v2 Physical Functioning scale: 18.0% with semaglutide against 6.6% with placebo. Semaglutide was ahead in every row, and in every row a substantial share of the placebo group crossed the same line. The abstract reports confirmed superiority on SF-36v2 physical functioning in STEP 1, 2 and 4; it does not list STEP 3.

What these questionnaires measure

A patient-reported outcome is a result measured by asking the participant directly, using a questionnaire that has been tested to show it measures what it claims to. The trials here used four kinds. The SF-36v2 is a general health survey used across many diseases. The KCCQ is specific to heart failure, and WOMAC to osteoarthritis.

The obesity-specific one is the IWQOL-Lite-CT, a 20-item questionnaire with a Physical domain (7 items) and a Psychosocial domain (13 items), plus a 5-item Physical Function composite. Its validation paper says it was developed and validated following FDA guidance on patient-reported outcomes, using data from two randomized trials. That paper is copyrighted to Novo Nordisk, which makes semaglutide, and the same lead author is a co-author of the STEP 1–4 analysis above.

Four reasons to read these scores carefully

  1. Placebo groups improve

    Joining a trial brings diet counseling, regular visits and attention. In STEP 9, both groups received counseling on physical activity and a reduced-calorie diet, and knee pain fell 27.5 points without the drug.

  2. The manufacturer paid for every trial here

    Each paper records manufacturer funding, and all four list authors affiliated with the manufacturer. That is normal for registration trials and does not make the results wrong, but no independent trial is in this set.

  3. Grouping by weight lost is not a randomized comparison

    SURMOUNT-1’s largest figures come from sorting participants by how much weight they lost. People who lose more may differ in other ways, so the gradient shows association, not that losing more weight caused the better scores.

  4. Physical scores moved more than mental ones

    In the SURMOUNT-1 group that lost 20% or more of their weight, the SF-36v2 Physical Component Summary rose 4.60 points and the Mental Component Summary rose 0.80. In STEP 2, the SF-36v2 Role Emotional scale was the one scale not numerically improved.

Where patient-reported measures come from

A questionnaire is only as good as the questions in it, and the most useful ones are built by asking patients what matters to them before any item is written. One documented example is the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ), which researchers developed from discussions in an online patient community: 30 questions in three subscales, tested on 431 respondents out of 1,209 invited. It was hosted on a platform built for exactly this kind of work, and we explain what happened to the Open Research Exchange and where its instruments can still be read.

For the measurement problem on the other side of this page, what a scan says about muscle rather than what a person says about function, see how to read lean-mass findings.

Frequently asked questions

Do GLP-1 drugs improve quality of life?

In the manufacturer-funded trials reviewed here, people on semaglutide or tirzepatide reported better physical function and weight-related quality of life than people on placebo. Mental-health scores moved much less: in SURMOUNT-1, the SF-36v2 Mental Component Summary rose 0.80 points even among people who lost 20% or more of their weight.

Was quality of life ever the main thing a GLP-1 trial measured?

Yes, in 2 of the trials reviewed here. In STEP-HFpEF, the heart-failure questionnaire KCCQ was a primary endpoint alongside body weight. In STEP 9, knee pain on the WOMAC scale was a primary endpoint alongside body weight.

Did people on placebo feel better too?

Yes. In STEP 9, knee pain fell 27.5 points with placebo against 41.7 with semaglutide. In STEP 1, 2 and 4, between 6.6% and 29.5% of placebo participants reached the threshold for a meaningful personal change in physical function.

What is a patient-reported outcome?

A result measured by asking the participant directly, using a questionnaire tested to show it measures what it claims to, rather than by a scale, a blood test or a clinician's assessment.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

  1. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF TrialCirculation 2024;149(3):204–216 (Kosiborod et al.)Supports: STEP-HFpEF: Kansas City Cardiomyopathy Questionnaire (KCCQ).
  2. Once-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisNew England Journal of Medicine 2024;391(17):1573–1583 (Bliddal et al.)Supports: STEP 9: WOMAC pain score (0–100), SF-36v2 physical function.
  3. Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trialsDiabetes, Obesity and Metabolism 2024;26(7):2945–2955 (Rubino et al.)Supports: STEP 1–4: IWQOL-Lite-CT (STEP 1 and 2), SF-36v2 (STEP 1–4).
  4. Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 studyDiabetes, Obesity and Metabolism 2025;27(2):539–550 (Gudzune et al.)Supports: SURMOUNT-1: IWQOL-Lite-CT, SF-36v2, EQ-5D-5L.
  5. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials VersionClinical Obesity 2019;9(3):e12310 (Kolotkin et al.)Supports: Structure and validation of the IWQOL-Lite-CT, developed following FDA guidance on patient-reported outcomes.
  6. Use of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)Journal of Medical Internet Research 2011;13(1):e12 (Wicks et al.)Supports: How a patient-reported instrument was built with an online patient community.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.